Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Ovaries Develop an Intriguing Second Role After Menopause : ScienceAlert (opens in a new tab)

sciencealert.com · 2026-10-14

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One key claim is not backed by the study. 2 other points were not covered by the paper.

  • 1 supported
  • 1 overstated
  • 1 not supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

Two claims go beyond the study. One overstates it and one isn't supported at all. Two claims the study doesn't address.

  • 1 supported
  • 1 overstated
  • 1 not supported
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not supportedThe study used mass spectrometry on healthy ovaries from 28 postmenopausal women aged 50-59, 60-69, and 70+ and found that protein profiles changed progressively with age, including a core set of seventeen proteins.View evidenceHide evidence

As stated28 women; three age groups; seventeen proteins

Why this verdict

The methods and broad finding are supported: DIA mass spectrometry was performed on healthy/non-pathological ovaries from 28 postmenopausal women in 50–59, 60–69, and ≥70 groups, and proteome profiles shifted with age. However, the stated “core set of seventeen proteins” is not supported by the abstract profile, which reports 117 significantly altered proteins in the ≥70 vs 50–59 comparison and a 26-protein BuckPOMS consensus signature.

1

Study evidence

Progressive, age-associated changes in the postmenopausal ovarian proteome were observed across donors aged 50–75, with 5,812 proteins quantified and 117 proteins significantly altered in the ≥70 versus 50–59 comparison.117 proteins (≥70 vs 50–59) identified as significantly altered

“We analyzed the proteomes of healthy, non‐pathological ovaries using mass spectrometry (data‐independent acquisition) from 28 postmenopausal women (50–75 years old), stratified into three age groups (50–59, 60–69, ≥ 70).”
2

Study evidence

A convergent set of age-associated proteins identified across differential abundance, multivariate modeling, and covariate-adjusted linear modeling was integrated into a 26-protein consensus signature termed BuckPOMS.

“Across differential abundance, multivariate modeling, and covariate‐adjusted linear modeling, we identified a convergent set of age‐associated proteins that were integrated into the 26‐protein Buck Postmenopausal Ovary Molecular Signature (BuckPOMS)”
Claim 2 of 5OverstatedThe story says these age-related tissue and immune changes may create a collagen-rich, fibrotic inflammatory environment that is ideal for tumors and could help explain increased ovarian cancer risk after menopause.View evidenceHide evidence

Why this verdict

The abstract profile supports age-associated extracellular matrix/matrisome remodeling, inflammatory signaling, and damage-associated secretory factors in healthy postmenopausal ovaries. It does not show that these changes create an environment “ideal for tumors” or explain increased ovarian cancer risk after menopause. Even though the story hedges with “may/could,” the cancer-risk mechanism goes beyond the observational, non-pathological tissue evidence available here.

1

Study evidence

Progressive, age-associated changes in the postmenopausal ovarian proteome were observed across donors aged 50–75, with 5,812 proteins quantified and 117 proteins significantly altered in the ≥70 versus 50–59 comparison.117 proteins (≥70 vs 50–59) identified as significantly altered

“We analyzed the proteomes of healthy, non‐pathological ovaries using mass spectrometry (data‐independent acquisition) from 28 postmenopausal women (50–75 years old), stratified into three age groups (50–59, 60–69, ≥ 70).”
2

Study evidence

Pathway enrichment of proteomic data shows increased inflammatory pathway signatures, increased matrisome/ECM remodeling pathways, and increased abundance of damage-associated secretory factors in older (decades postmenopause) ovaries.

“Pathway enrichment further identified an increase in inflammatory and matrisome pathways, and increased abundance of damage-associated secretory factors decades following menopause.”
Claim 3 of 5Not coveredAccording to the article, younger postmenopausal ovaries had more proteins tied to RNA/DNA regulation and tissue maintenance, while ovaries from the oldest group had more proteins involved in lipid metabolism, innate immunity, and inflammation.View evidenceHide evidence

As statedseventeen proteins

Why this verdict

The abstract profile supports the general direction of functional change: younger postmenopausal ovaries showed RNA/gene-regulatory signatures, while older ovaries showed metabolic, innate immune/complement, matrisome, and inflammatory pathway shifts. But the story’s more specific annotations—especially lipid metabolism, DNA regulation, tissue maintenance, and the implied seventeen-protein basis—are not fully verifiable from the abstract-level profile.

1

Study evidence

Progressive, age-associated changes in the postmenopausal ovarian proteome were observed across donors aged 50–75, with 5,812 proteins quantified and 117 proteins significantly altered in the ≥70 versus 50–59 comparison.117 proteins (≥70 vs 50–59) identified as significantly altered

“We analyzed the proteomes of healthy, non‐pathological ovaries using mass spectrometry (data‐independent acquisition) from 28 postmenopausal women (50–75 years old), stratified into three age groups (50–59, 60–69, ≥ 70).”
2

Study evidence

Pathway enrichment of proteomic data shows increased inflammatory pathway signatures, increased matrisome/ECM remodeling pathways, and increased abundance of damage-associated secretory factors in older (decades postmenopause) ovaries.

“Pathway enrichment further identified an increase in inflammatory and matrisome pathways, and increased abundance of damage-associated secretory factors decades following menopause.”
Claim 4 of 5Not coveredThe article frames the findings as potentially useful for future biomarkers, therapies to lower ovarian cancer risk, and broader understanding of postmenopausal health.View evidenceHide evidence

Why this verdict

The profile supports broad potential implications for postmenopausal women’s health and identifies age-associated ovarian proteomic signatures, which could motivate future work. But the abstract-level evidence does not verify the specific translational framing around future biomarkers or therapies to lower ovarian cancer risk.

1

Study evidence

Progressive, age-associated changes in the postmenopausal ovarian proteome were observed across donors aged 50–75, with 5,812 proteins quantified and 117 proteins significantly altered in the ≥70 versus 50–59 comparison.117 proteins (≥70 vs 50–59) identified as significantly altered

“We analyzed the proteomes of healthy, non‐pathological ovaries using mass spectrometry (data‐independent acquisition) from 28 postmenopausal women (50–75 years old), stratified into three age groups (50–59, 60–69, ≥ 70).”
2

Study evidence

A convergent set of age-associated proteins identified across differential abundance, multivariate modeling, and covariate-adjusted linear modeling was integrated into a 26-protein consensus signature termed BuckPOMS.

“Across differential abundance, multivariate modeling, and covariate‐adjusted linear modeling, we identified a convergent set of age‐associated proteins that were integrated into the 26‐protein Buck Postmenopausal Ovary Molecular Signature (BuckPOMS)”
Claim 5 of 5SupportedResearchers led by Francesca Duncan and Birgit Schilling published a new study in Aging Cell suggesting that ovaries after menopause are not simply inactive, but undergo an age-related biological shift.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the core scientific framing: postmenopausal ovaries were profiled across age strata and showed progressive age-associated proteome remodeling, supporting the idea that they are not biologically inert after menopause. The supplied profile does not independently verify the named study leaders, but the paper finding itself is supported.

1

Study evidence

Progressive, age-associated changes in the postmenopausal ovarian proteome were observed across donors aged 50–75, with 5,812 proteins quantified and 117 proteins significantly altered in the ≥70 versus 50–59 comparison.117 proteins (≥70 vs 50–59) identified as significantly altered

“We analyzed the proteomes of healthy, non‐pathological ovaries using mass spectrometry (data‐independent acquisition) from 28 postmenopausal women (50–75 years old), stratified into three age groups (50–59, 60–69, ≥ 70).”
2

Study evidence

A convergent set of age-associated proteins identified across differential abundance, multivariate modeling, and covariate-adjusted linear modeling was integrated into a 26-protein consensus signature termed BuckPOMS.

“Across differential abundance, multivariate modeling, and covariate‐adjusted linear modeling, we identified a convergent set of age‐associated proteins that were integrated into the 26‐protein Buck Postmenopausal Ovary Molecular Signature (BuckPOMS)”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • A 26-protein BuckPOMS consensus signature derived across differential abundance, multivariate modeling, and covariate-adjusted linear modeling.

    The paper profile identifies a 26-protein BuckPOMS signature, whereas the story presentation says there was a core set of seventeen proteins. That does not accurately reflect the material signature described in the abstract profile.

    From proteomics feature selection and consensus integration

  • Immunohistochemistry validation of selected BuckPOMS proteins, including WNT4 and Fibromodulin/FMOD.

    The supplied story presentation does not mention the paper’s IHC validation of representative proteins.

    From immunohistochemistry validation

  • Key limitation: the study is cross-sectional, so it cannot establish within-individual aging trajectories or causal temporal dynamics.

    The story caveats mention tumor-free/non-diseased tissue and hedge the cancer mechanism, but they do not identify the cross-sectional design as limiting causal or longitudinal inference.

    From cross-sectional proteomic observational study

  • Key limitation: findings come from healthy, non-pathological postmenopausal ovaries and may not generalize to diseased/pathological states such as ovarian cancer.

    The story notes the tissue was tumor-free and presents the cancer explanation as a possibility, but it still uses the findings to discuss ovarian cancer risk and does not clearly state that the study did not directly examine cancer or pathological ovaries.

    From cross-sectional proteomic observational study

3 things the story did carry across
  • Cross-sectional DIA-MS proteomic profiling of 28 healthy, non-pathological postmenopausal human ovaries aged 50–75, stratified into 50–59, 60–69, and ≥70 groups.
  • Progressive age-associated remodeling of the postmenopausal ovarian proteome, including 5,812 quantified protein groups and 117 significantly altered proteins in the ≥70 vs 50–59 comparison.
  • Functional/pathway interpretation: shifts from RNA/gene-regulatory signatures in younger postmenopausal ovaries toward metabolic, innate immune/complement, matrisome/extracellular matrix, inflammatory, and damage-associated secretory factor signatures with age.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

ex vivo human

1Lead resultex vivo humanDefine how the postmenopausal human ovary proteome changes across decades after menopause (50–75 years), including differential abundance and multivariate separation by age group.cross-sectional proteomic observational studyExpand

In plain English

Cross-sectional DIA-MS proteomic profiling of 28 healthy, non-pathological postmenopausal human ovaries (ages 50–75, grouped 50–59, 60–69, ≥70) quantified 5,812 protein groups and identified progressive, age-associated proteome remodeling, including 117 proteins significantly altered in the ≥70 versus 50–59 comparison. Multivariate analyses separated younger (50–59) and older (≥70) cohorts and indicated a shift in dominant functional signatures from RNA/gene-regulatory processes in younger ovaries toward metabolic, trafficking, and innate immune/complement and matrisome pathways in older ovaries. Integration of differential abundance, multivariate modeling, and covariate‑adjusted linear models produced a 26‑protein consensus (BuckPOMS) capturing extracellular matrix remodeling, inflammatory signaling, and loss of structural/keratin-associated proteins; representative matrisome proteins (WNT4, FMOD) were validated by immunohistochemistry.

Key findings

  • Progressive, age-associated changes in the postmenopausal ovarian proteome were observed across donors aged 50–75, with 5,812 proteins quantified and 117 proteins significantly altered in the ≥70 versus 50–59 comparison.117 proteins (≥70 vs 50–59) identified as significantly altered
  • Multivariate analyses showed clear separation between 50–59 and ≥70 age cohorts and indicated functional shifts from RNA/gene‑regulatory signatures in younger ovaries toward metabolic, trafficking, innate immune/complement, and matrisome/inflammatory pathways in older ovaries.
“We analyzed the proteomes of healthy, non‐pathological ovaries using mass spectrometry (data‐independent acquisition) from 28 postmenopausal women (50–75 years old), stratified into three age groups (50–59, 60–69, ≥ 70).”
What this piece can’t prove
  • Cross-sectional design with 28 donors limits inference about within-individual temporal dynamics; observed patterns represent between-person differences across age strata.
  • Findings are restricted to healthy, non‑pathological postmenopausal ovaries and may not generalize to pathological conditions or broader populations.

2 further details could not be confirmed from the summary.

2secondary dataDerive a consensus age-associated protein signature (BuckPOMS) that captures progressive molecular remodeling in the postmenopausal ovary and is supported across multiple modeling approaches.proteomics feature selection and consensus integrationExpand

In plain English

The authors derived a 26-protein consensus age-associated signature (Buck Postmenopausal Ovary Molecular Signature, BuckPOMS) by integrating convergent proteins identified across differential abundance testing, multivariate modeling, and covariate-adjusted linear modeling of DIA mass-spectrometry proteomes from 28 postmenopausal human ovaries (ages 50–75). BuckPOMS captures progressive extracellular matrix remodeling, inflammatory signaling, and loss of structural and keratin-associated proteins; representative proteins (WNT4, FMOD) were validated by immunohistochemistry.

Key findings

  • A convergent set of age-associated proteins identified across differential abundance, multivariate modeling, and covariate-adjusted linear modeling was integrated into a 26-protein consensus signature termed BuckPOMS.
  • BuckPOMS captures progressive extracellular matrix remodeling, increased inflammatory signaling, and loss of structural and keratin-associated proteins with increasing postmenopausal age.
“Across differential abundance, multivariate modeling, and covariate‐adjusted linear modeling, we identified a convergent set of age‐associated proteins that were integrated into the 26‐protein Buck Postmenopausal Ovary Molecular Signature (BuckPOMS)”
What this piece can’t prove
  • Analysis is based on 28 postmenopausal ovarian samples (ages 50–75); sample size is modest.
  • The abstract does not report detailed feature-selection criteria, model specifications, or statistical thresholds used to derive the 26-protein consensus.

2 further details could not be confirmed from the summary.

3ex vivo humanValidate selected BuckPOMS proteins (e.g., WNT4, FMOD) in postmenopausal ovary tissue by immunohistochemistry.immunohistochemistry validationExpand

In plain English

The paper reports immunohistochemistry (IHC) validation of selected proteins from the BuckPOMS consensus signature in postmenopausal human ovary tissue; examples explicitly named in the abstract are the secreted matrisome proteins WNT4 and Fibromodulin (FMOD).

Key findings

  • Representative BuckPOMS proteins, including the secreted matrisome proteins WNT4 and Fibromodulin (FMOD), were validated by immunohistochemistry in postmenopausal ovary tissue.
“Representative BuckPOMS proteins, including the secreted matrisome proteins WNT4 and Fibromodulin (FMOD), were validated by immunohistochemistry.”
What this piece can’t prove
  • Extent and representativeness of validation (how many BuckPOMS proteins were tested beyond the examples) are not specified.
  • Because only an abstract statement is available, methodological rigor and reproducibility of the IHC results cannot be assessed from the provided text.

1 further detail could not be confirmed from the summary.

4secondary dataInterpret proteomic changes via pathway enrichment to highlight extracellular matrix/matrisome remodeling, inflammatory/complement signaling, and damage-associated secretory factors with increasing age.Pathway enrichment of age-associated proteomic changes (secondary analysis)Expand

In plain English

Pathway enrichment analysis of age-associated proteomic changes in postmenopausal human ovaries identified increased inflammatory and matrisome/extracellular matrix pathways and an increased abundance of damage-associated secretory factors with advancing age.

Key findings

  • Pathway enrichment of proteomic data shows increased inflammatory pathway signatures, increased matrisome/ECM remodeling pathways, and increased abundance of damage-associated secretory factors in older (decades postmenopause) ovaries.
“Pathway enrichment further identified an increase in inflammatory and matrisome pathways, and increased abundance of damage-associated secretory factors decades following menopause.”
What this piece can’t prove
  • Cohort/sample size and group stratification are reported (28 women across three age groups), but how sample size and covariates were handled in enrichment is not described.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

The Human Ovary Exhibits Dynamic Molecular Remodeling in the Decades Post‐Menopause

Aging Cell · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Candidate

Evaluating and Optimizing Mass Spectrometry Proteomics Data to Deconvolve Cell-Type-Specific Protein Expression in Tumors

Crossref

Source (opens in a new tab)

And 10 more candidates considered.